RU-58841

RU-58841 is a non-steroidal, purely antagonistic androgen receptor blocker built on an aryl-hydantoin scaffold, first synthesized at Roussel Uclaf in France ^[1]. It was engineered specifically for topical use, with high affinity for androgen receptors in skin appendages and a design intent that it act at the site of application while producing minimal systemic antiandrogenic activity ^[1][5]. In the scientific literature it is described as a candidate for the treatment of androgen-dependent skin disorders including acne, androgenetic alopecia, and hirsutism ^[1].

The compound has a long preclinical history. Classic studies used the hamster flank organ and Syrian hamster sebaceous gland models to show that topically applied RU-58841 causes dose-dependent regression of androgen-driven structures, with local potency exceeding older agents such as cyproterone acetate ^[3]. In a stumptailed macaque model of androgenetic alopecia, topical application increased hair density, thickness, and length without detectable systemic effects, while cell-based assays confirmed competitive antagonism of the wild-type androgen receptor comparable to hydroxyflutamide ^[2]. Formulation science has explored prodrugs such as RU 58841-myristate and lipid nanoparticle carriers to target the follicle and sebaceous gland pathway ^[4][6].

RU-58841 was never approved as a medicine and its clinical development was discontinued, so it exists today as a research chemical rather than a licensed drug; there is no formal regulatory approval, and human data are limited ^[1][2]. It is typically prepared as a topical solution for research use. Its enduring appeal rests on the pharmacological premise of a local antiandrogen that can address the hormonal driver of pattern hair loss at the scalp while sparing circulating hormone levels ^[1][5].

RU-58841 was never approved and never completed human trials, so its safety in people is uncharacterized, and research-grade purity varies. Systemic absorption could in principle suppress the androgen axis, and reported user effects range from scalp irritation to hormonal-type symptoms. Research use only.

RU-58841 was synthesized at the Centre de Recherches Roussel Uclaf in Romainville, France, and first described in the scientific literature by Battmann and colleagues in 1994 as a new non-steroidal, topically active antiandrogen intended for acne, androgenetic alopecia and hirsutism. Its defining feature from the outset was site-restricted action; in hamster models it produced potent local regression of androgen-dependent skin structures at microgram doses without disturbing systemic testosterone. After Roussel Uclaf was absorbed into successor pharmaceutical companies during the 1990s, the compound was never brought to market as an approved drug, and later work focused on delivery, including a myristate ester prodrug reported by Munster and colleagues in 2005. Having lapsed from formal development, it has persisted chiefly as a widely discussed research chemical for hair loss.

RU-58841 is frequently cited as one of the most studied local antiandrogens for hair loss, and its appeal is easy to understand; decades of animal research show striking regression of androgen-dependent skin structures, and its rapid local metabolism is designed to keep hormonal effects concentrated at the scalp rather than throughout the body. That targeted-action concept is what draws people who want to block follicular DHT without the systemic side effects associated with oral antiandrogens. Honesty requires noting that the compelling data are almost entirely preclinical; it was never completed through human clinical trials, it has no regulatory approval, and long-term human safety is not established. It is best viewed as a promising but investigational topical agent rather than a proven therapy.